These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 15991268

  • 21. [Changes of proinflammatory cytokines and their receptors in serum from patients with pulmonary tuberculosis].
    Tang S, Xiao H, Fan Y, Wu F, Zhang Z, Li H, Yang Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):325-9. PubMed ID: 12126553
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
    Wierzbowska A, Urbańska-Ryś H, Robak T.
    Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
    [Abstract] [Full Text] [Related]

  • 24. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H, Wiersbowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [Abstract] [Full Text] [Related]

  • 25. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
    Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV.
    Leukemia; 2004 Mar; 18(3):624-7. PubMed ID: 14749707
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J.
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [Abstract] [Full Text] [Related]

  • 28. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
    Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitriadou EM, Kalpadakis C, Tsionos K, Panayiotidis P, Dimopoulos MA, Pangalis GA, Kyrtsonis MC, Greek Myeloma Study Group.
    Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
    [Abstract] [Full Text] [Related]

  • 29. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M, Scudla V, Adam Z, Gregora E, Pour L, Minarik J, Pavlicek P, Pika T, Bacovsky J.
    Neoplasma; 2008 Mar; 55(4):345-9. PubMed ID: 18505347
    [Abstract] [Full Text] [Related]

  • 30. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D.
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [Abstract] [Full Text] [Related]

  • 31. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM.
    Cancer; 2003 May 15; 97(10):2440-52. PubMed ID: 12733143
    [Abstract] [Full Text] [Related]

  • 32. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
    Brenne AT, Romstad LH, Gimsing P, Juliusson G, Turesson I, Romundstad P, Borset M, Sundan A, Waage A.
    Haematologica; 2004 May 15; 89(5):552-6. PubMed ID: 15136218
    [Abstract] [Full Text] [Related]

  • 33. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS.
    Am J Hematol; 2003 Apr 15; 72(4):229-33. PubMed ID: 12666132
    [Abstract] [Full Text] [Related]

  • 34. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
    Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M.
    Haematologica; 2001 Apr 15; 86(4):399-403. PubMed ID: 11325646
    [Abstract] [Full Text] [Related]

  • 35. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V, Kubalová D, Bacovský J, Lukes J, Vavrdová V.
    Cas Lek Cesk; 1996 Nov 20; 135(22):719-22. PubMed ID: 8998823
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
    Wasser K, Moehler T, Neben K, Nosas S, Heiss J, Goldschmidt H, Hillengass J, Düber C, Kauczor HU, Delorme S.
    Rofo; 2004 Sep 20; 176(9):1285-95. PubMed ID: 15346264
    [Abstract] [Full Text] [Related]

  • 40. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.
    Eur J Haematol; 2007 Apr 20; 78(4):297-302. PubMed ID: 17286608
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.